KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lam Research (LRCX) EBT (2016 - 2026)

Lam Research has reported EBT over the past 18 years, most recently at $2.0 billion for Q1 2026.

  • For Q1 2026, EBT rose 30.9% year-over-year to $2.0 billion; the TTM value through Mar 2026 reached $7.5 billion, up 40.36%, while the annual FY2025 figure was $6.0 billion, 36.65% up from the prior year.
  • EBT for Q1 2026 was $2.0 billion at Lam Research, up from $1.8 billion in the prior quarter.
  • Over five years, EBT peaked at $2.0 billion in Q1 2026 and troughed at $863.6 million in Q2 2023.
  • A 5-year average of $1.4 billion and a median of $1.3 billion in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: plummeted 38.02% in 2023 and later skyrocketed 54.11% in 2025.
  • Year by year, EBT stood at $1.7 billion in 2022, then crashed by 34.2% to $1.1 billion in 2023, then increased by 24.02% to $1.3 billion in 2024, then surged by 36.23% to $1.8 billion in 2025, then rose by 9.53% to $2.0 billion in 2026.
  • Business Quant data shows EBT for LRCX at $2.0 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.9 billion in Q3 2025.